Let's face it, investors -- FDA decisions can be confusing.

Delays in particular can be difficult to decipher. They can sometimes signal serious problems that investors need to be wary of, and other times they just mean that the agency needs more time to analyze data. In the following video, our health care analyst Max Macaluso looks at how FDA delays can affect investors, and he draws from recent examples at fledgling orphan drugmaker Raptor Pharmaceutical , Eliquis developers Pfizer and Bristol-Myers Squibb , obesity drugmaker VIVUS , and inhalable insulin developer MannKind .


The health care space may offer investors many opportunities, but this is also one of the market's riskiest sectors. Motley Fool co-founder David Gardner's picks, which range across many sectors, have frequently trounced the market.

How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.

The article Are FDA Delays Good or Bad for Investors? originally appeared on Fool.com.

Max Macaluso, Ph.D. owns shares of Raptor Pharmaceutical. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Introduction to ETFs

The basics of Exchange Traded Funds and why ETFs are hot.

View Course »

Investing in Startups

The lucrative and risky world of startups.

View Course »

Add a Comment

*0 / 3000 Character Maximum